Trial · NCT02564536
Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
NCT02564536, Phase 1, Withdrawn, Washington University School of Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS). Trials, record NCT02564536. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02564536
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)
- NCT number
- NCT02564536
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- Washington University School of Medicine
- Conditions
- Chronic Myelomonocytic Leukemia, Juvenile Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic Syndromes, Myelofibrosis
- Interventions
- Pacritinib, Decitabine
- First posted
- 2015-09-30
- Last updated
- 2017-05-08
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety of regimen as measured by adverse events | 30 days after completion of treatment (up to 1 year) | The descriptions and grading for adverse events are found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 |
| Secondary | Rate of objective response as defined by the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) consensus | End of treatment (up to 48 weeks) | Objective response is defined as CR (complete remission/response) + PR (partial remission/response) + CI (clinical improvement). |
| Secondary | Rate of hematologic response | End of treatment (up to 48 weeks) | -Anemia response Anemia response is only applicable for patients with baseline hemoglobin level less than 10g/dL for 8 weeks or more and requires: \*≥2 g/dL increase in hemoglobin level \*becoming transfusion-independent (no RBC transfusions in past 1 month) -Platelet response Platelet response is only applicable for patients with a baseline platelet count of less than 50 x 10\^9/L for 8 weeks or more, and requires: * 100% increase in platelet count AND * An absolute platelet count of at least 50 x 10\^9/L |
| Secondary | Rate of symptom response as measured by the total symptom score (TSS) | End of treatment (up to 48 weeks) | A ≥50% reduction in the myeloproliferative neoplasm symptom assessment total symptom score |
| Secondary | Rate of spleen response | End of treatment (up to 48 weeks) | * A baseline splenomegaly that is palpable at 5-10 cm below the left costal margin becomes not palpable OR * A baseline splenomegaly that is palpable \> 10 cm below the left costal margin decreases by ≥50% OR * A baseline splenomegaly that is palpable \< 5 cm below the left costal margin is not eligible for spleen response OR * MRI or CT shows ≥35% spleen volume reduction |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02564536
GET https://conductscience.org/api/trials/v1/NCT02564536/registered